Acetaminophen overdose resident survival guide: Difference between revisions
No edit summary |
|||
Line 5: | Line 5: | ||
==Definition== | ==Definition== | ||
[[Acetaminophen]] overdose/toxicity occurs when there is intentional, accidental, acute and/or chronic ingestion of supratherapeutic doses of [[acetaminophen]] ([[paracetamol]]). | [[Acetaminophen]] overdose/toxicity occurs when there is intentional, accidental, acute and/or chronic ingestion of supratherapeutic doses of [[acetaminophen]]([[paracetamol]]). | ||
It is the most widely used OTC (over the counter) analgesic in USA. It is available in the U.S market under the following brand names. <br> | It is the most widely used OTC (over the counter) analgesic in USA. It is available in the U.S. market under the following brand names. <br> | ||
<div class="mw-collapsible-content"> | <div class="mw-collapsible-content"> | ||
<div class="mw-collapsible mw-collapsed"> | <div class="mw-collapsible mw-collapsed"> | ||
Line 31: | Line 31: | ||
==Common dosage forms and strengths== | ==Common dosage forms and strengths== | ||
#Suppository: 120 mg, 125 mg, 325 mg, 650 mg | # Suppository: 120 mg, 125 mg, 325 mg, 650 mg | ||
#Chewable tablets: 80 mg | # Chewable tablets: 80 mg | ||
#Regular strength: 325 mg | # Regular strength: 325 mg | ||
#Extra strength: 500 mg | # Extra strength: 500 mg | ||
#Liquid: 160 mg/teaspoon | # Liquid: 160 mg/teaspoon | ||
#Drops: 100 mg / mL, 120 mg / 2.5 mL | # Drops: 100 mg / mL, 120 mg / 2.5 mL | ||
==Toxic Dose== | ==Toxic Dose== | ||
Line 48: | Line 48: | ||
{{familytree | | | | | | | | A01 | | | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Take focused history:''' <br> ❑ Time since last ingestion <br> ❑ Number of tablets/other dosing form taken <br> ❑ Frequency of dosage </div>}} | {{familytree | | | | | | | | A01 | | | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Take focused history:''' <br> ❑ Time since last ingestion <br> ❑ Number of tablets/other dosing form taken <br> ❑ Frequency of dosage </div>}} | ||
{{familytree | | | | | | | | |!| | | | | | }} | {{familytree | | | | | | | | |!| | | | | | }} | ||
{{familytree | | | | | | | | B01 |B01=<div style="float: left; text-align: left; line-height: 150% ">'''Characterize the symptoms & examine the patient:'''<br>'''Stage I:''' First 24 hours <br> ❑ Asymptomatic <br> ❑ Nausea & vomiting <br> ❑ Diaphoresis <br> ❑ Anion gap metabolic acidosis & coma (with massive doses) | {{familytree | | | | | | | | B01 |B01=<div style="float: left; text-align: left; line-height: 150% ">'''Characterize the symptoms & examine the patient:'''<br>'''Stage I:''' First 24 hours <br> ❑ Asymptomatic <br> ❑ Nausea & vomiting <br> ❑ Diaphoresis <br> ❑ [[High anion gap metabolic acidosis critical pathways|Anion gap metabolic acidosis]] & coma (with massive doses) | ||
---- | ---- | ||
'''Stage II:''' 24 to 72 hours <br> Clinical & lab features of hepatotoxicity | '''Stage II:''' 24 to 72 hours <br> Clinical & lab features of hepatotoxicity | ||
Line 54: | Line 54: | ||
:❑ Deranged LFT's, PT, Serum bilirubin | :❑ Deranged LFT's, PT, Serum bilirubin | ||
Clinical & lab features of nephrotoxicity | Clinical & lab features of nephrotoxicity | ||
:❑ Oligouria, hematuria | :❑ [[Oligouria]], [[hematuria]] | ||
:❑ Deranged RFT's, proteinuria, hematuria, casts | :❑ Deranged RFT's, proteinuria, hematuria, casts | ||
---- | ---- | ||
Line 62: | Line 62: | ||
: ❑ Impaired consciousness <br> | : ❑ Impaired consciousness <br> | ||
: ❑ Asterixis <br> | : ❑ Asterixis <br> | ||
: ❑ Foetur hepaticus <br> | : ❑ [[Foetur hepaticus]] <br> | ||
: ❑ Haemorrhage <br> | : ❑ Haemorrhage <br> | ||
Labs consistent with severe liver failure <br> | Labs consistent with severe liver failure <br> | ||
: ❑ AST/ALT levels > 1000 mg/Dl <br> | : ❑ [[AST]]/[[ALT]] levels > 1000 mg/Dl <br> | ||
: ❑ Prolonged PT/INR <br> | : ❑ Prolonged [[PT]]/[[INR]] <br> | ||
: ❑ Hypogycemia <br> | : ❑ Hypogycemia <br> | ||
: ❑ Lactic <br> | : ❑ Lactic acidosis <br> | ||
: ❑ Total bilirubin > 4.0 <br> | : ❑ Total bilirubin > 4.0 <br> | ||
❑ Renal failure <br> ❑ Death from multiorgan system failure | ❑ Renal failure <br> ❑ Death from multiorgan system failure | ||
Line 83: | Line 83: | ||
:* Activated charcoal 1g/Kg max 50 Kg <br> | :* Activated charcoal 1g/Kg max 50 Kg <br> | ||
❑ Supportive care <br> | ❑ Supportive care <br> | ||
:* Fluid | :* Fluid resuscitation | ||
:* Symptomatic treatment of nausea & vomiting | :* Symptomatic treatment of nausea & vomiting | ||
:* If liver failure established consider for liver | :* If liver failure established consider for liver transplant (see box below) </div> }} | ||
{{familytree | | | | |!| | | | | | | |!| | | | }} | {{familytree | | | | |!| | | | | | | |!| | | | }} | ||
{{familytree | | | | F01 | | | | | | F02 | | | |F01=<div style="float: left; text-align: left; line-height: 150% ">Initiate N-acetlycysteine therapy if, one or more true: <br> ❑ Acetaminophen concentration above nomogram line <br> ❑ AST is elevated <br> ❑ Serum acetaminophen concentration > 10 mcg/mL </div>|F02=<div style="float: left; text-align: left; line-height: 150% ">Initiate N-acetlycysteine therapy if, one or more true: <br> ❑ AST is elevated <br> ❑ Serum acetaminophen concentration > 10 mcg/mL </div> }} | {{familytree | | | | F01 | | | | | | F02 | | | |F01=<div style="float: left; text-align: left; line-height: 150% ">Initiate [[N-acetlycysteine therapy]] if, one or more true: <br> ❑ Acetaminophen concentration above nomogram line <br> ❑ AST is elevated <br> ❑ Serum acetaminophen concentration > 10 mcg/mL </div>|F02=<div style="float: left; text-align: left; line-height: 150% ">Initiate [[N-acetlycysteine]] therapy if, one or more true: <br> ❑ AST is elevated <br> ❑ Serum acetaminophen concentration > 10 mcg/mL </div> }} | ||
{{familytree | | | | |`|-|-|-|v|-|-|-|'| | | | | | }} | {{familytree | | | | |`|-|-|-|v|-|-|-|'| | | | | | }} | ||
{{familytree | | | | | | | | G01 | | | | | | | | |G01=<div style="float: left; text-align: left; line-height: 150% "> '''N-acetylcysteine therapy:''' <br> ❑ Oral: 140 mg/Kg loading dose <br> followed by 70 mg/Kg 4 hourly for additional 17 doses <br> OR <br> ❑ IV: 150 mg/Kg in 200 cc D5W infused over 15 mins <br> followed by 50 mg/Kg in 500 cc D5W infused over 4 hours <br> then 100 mg/Kg in 1000 cc D5W over remaining 16 hours | {{familytree | | | | | | | | G01 | | | | | | | | |G01=<div style="float: left; text-align: left; line-height: 150% "> '''N-acetylcysteine therapy:''' <br> ❑ Oral: 140 mg/Kg loading dose <br> followed by 70 mg/Kg 4 hourly for additional 17 doses <br> OR <br> ❑ IV: 150 mg/Kg in 200 cc D5W infused over 15 mins <br> followed by 50 mg/Kg in 500 cc D5W infused over 4 hours <br> then 100 mg/Kg in 1000 cc D5W over remaining 16 hours | ||
---- | ---- | ||
IV route is referred in following cases (High risk patients): <br> ❑ Malnourished/eating disorders <br> ❑ Failure to thrive in children <br> ❑ AIDS <br> ❑ Alcoholism <br> ❑ Associated febrile illness <br> ❑ Using drugs that induce CYP2E1 p450 system <br> | IV route is referred in following cases (High risk patients): <br> ❑ Malnourished/eating disorders <br> ❑ Failure to thrive in children <br> ❑ AIDS <br> ❑ Alcoholism <br> ❑ Associated febrile illness <br> ❑ Using drugs that induce [[CYP2E1]] p450 system <br> | ||
:* Carbamazepine/phenytoin/phenobarbital | :* [[Carbamazepine]]/[[phenytoin]]/[[phenobarbital]] | ||
:* Rifampicin/rifabutin | :* [[Rifampicin]]/[[rifabutin]] | ||
:* Efavirenz/nevirapine <br> | :* [[Efavirenz]]/[[nevirapine]] <br> | ||
❑ Abnormal renal or hepatic function at presentation <br> Pregnancy </div> }} | ❑ Abnormal renal or hepatic function at presentation <br> Pregnancy </div> }} | ||
{{familytree | | | | | | | | |!| | | | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | | | }} | ||
{{familytree | | | | | | | | H01 | | | | | | | | |H01=<div style="float: left; text-align: left; line-height: 150% ">'''At the completion of therapy check for:''' <br> ❑ AST < 100 mg/dL <br> ❑ Serum acetaminophen levels < 10 mcg/mL </div> }} | {{familytree | | | | | | | | H01 | | | | | | | | |H01=<div style="float: left; text-align: left; line-height: 150% ">'''At the completion of therapy check for:''' <br> ❑ AST < 100 mg/dL <br> ❑ Serum acetaminophen levels < 10 mcg/mL </div> }} | ||
{{familytree | | | | |,|-|-|-|^|-|-|-|.| | | | | | | }} | {{familytree | | | | |,|-|-|-|^|-|-|-|.| | | | | | | }} | ||
{{familytree | | | | I01 | | | | | | I02 | | | | |I01=Yes |I02=No|border=0 }} | {{familytree | | | | I01 | | | | | | I02 | | | | |I01=Yes |I02=No|border=0 }} | ||
{{familytree | | | | |!| | | | | | | |!| | | | | | | }} | {{familytree | | | | |!| | | | | | | |!| | | | | | | }} | ||
{{familytree | | | | J01 | | | | | | J02 | | | | | |J01=Resolution |J02=<div style="float: left; text-align: left; line-height: 150% "> Continue therapy. Use following as end points of treatment: <br> ❑ Normalization of INR <br> ❑ Resolution of encephalopathy <br> ❑ Decreasing ALT </div> }} | {{familytree | | | | J01 | | | | | | J02 | | | | | |J01=Resolution |J02=<div style="float: left; text-align: left; line-height: 150% "> Continue therapy. Use following as end points of treatment: <br> ❑ Normalization of INR <br> ❑ Resolution of [[encephalopathy]] <br> ❑ Decreasing ALT </div> }} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 21:05, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]
Definition
Acetaminophen overdose/toxicity occurs when there is intentional, accidental, acute and/or chronic ingestion of supratherapeutic doses of acetaminophen(paracetamol).
It is the most widely used OTC (over the counter) analgesic in USA. It is available in the U.S. market under the following brand names.
Tylenol
Anacin-3
Liquiprin
Percocet
Tempra
Cold and flu medicines
Aceta
Actimin
Apacet>br>
Aspirin Free Anacin
Atasol
Banesin
Dapa
Datril Extra-Strength
Feverall
Fibi
Genapap
Genebs
Common dosage forms and strengths
- Suppository: 120 mg, 125 mg, 325 mg, 650 mg
- Chewable tablets: 80 mg
- Regular strength: 325 mg
- Extra strength: 500 mg
- Liquid: 160 mg/teaspoon
- Drops: 100 mg / mL, 120 mg / 2.5 mL
Toxic Dose
The toxic dose of paracetamol is highly variable. In individuals over 6 years of age, single doses above 200 mg/kg consumed over a single 24-hour period have a reasonable likelihood of causing toxicity. If an individual has consumed large quantities of paracetamol over a 48 hour period, a dose of above 6 grams or 150 mg/kg in the subsequent 24 hour period may cause toxicity.[1]
Management
Shown below is an algorithm summarizing the approach to Acetaminophen Overdose.
Take focused history: ❑ Time since last ingestion ❑ Number of tablets/other dosing form taken ❑ Frequency of dosage | |||||||||||||||||||||||||||||||||||||||
Characterize the symptoms & examine the patient: Stage I: First 24 hours ❑ Asymptomatic ❑ Nausea & vomiting ❑ Diaphoresis ❑ Anion gap metabolic acidosis & coma (with massive doses) Stage II: 24 to 72 hours
Clinical & lab features of nephrotoxicity Stage III: 72 to 96 hours
Labs consistent with severe liver failure
❑ Renal failure Stage IV: 4 days to 2 weeks ❑ Recovery | |||||||||||||||||||||||||||||||||||||||
Order labs: ❑ Serum paracetamol concentration ( @4 hours and 16 hours) ❑ Liver function tests (LFT's) ❑ Prothrombin time (PT) or International normalised ratio (INR) Renal function tests (RFT's) ❑ Chart Rumack Matthew nomogram (not useful for chronic overdose) | |||||||||||||||||||||||||||||||||||||||
Acute overdose (Single ingestion within a 4 hour period) | Chronic overdose (Multiple ingestions over more than 4 hours) | ||||||||||||||||||||||||||||||||||||||
❑ Begin therapy within 8 hours of ingestion ❑ Gastric decontamination
❑ Supportive care
| |||||||||||||||||||||||||||||||||||||||
Initiate N-acetlycysteine therapy if, one or more true: ❑ Acetaminophen concentration above nomogram line ❑ AST is elevated ❑ Serum acetaminophen concentration > 10 mcg/mL | Initiate N-acetlycysteine therapy if, one or more true: ❑ AST is elevated ❑ Serum acetaminophen concentration > 10 mcg/mL | ||||||||||||||||||||||||||||||||||||||
N-acetylcysteine therapy: ❑ Oral: 140 mg/Kg loading dose followed by 70 mg/Kg 4 hourly for additional 17 doses OR ❑ IV: 150 mg/Kg in 200 cc D5W infused over 15 mins followed by 50 mg/Kg in 500 cc D5W infused over 4 hours then 100 mg/Kg in 1000 cc D5W over remaining 16 hours IV route is referred in following cases (High risk patients): Pregnancy | |||||||||||||||||||||||||||||||||||||||
At the completion of therapy check for: ❑ AST < 100 mg/dL ❑ Serum acetaminophen levels < 10 mcg/mL | |||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||
Resolution | Continue therapy. Use following as end points of treatment: ❑ Normalization of INR ❑ Resolution of encephalopathy ❑ Decreasing ALT | ||||||||||||||||||||||||||||||||||||||
Criteria for possible liver transplantation:
| |||||||||||||
The following algorithm is based on guidelines from "Management of paracetamol poisoning" [2] and "Acetaminophen toxicity and treatment" [3] published by American college of emergency physicians.
References
- ↑ Dart RC, Erdman AR, Olson KR, Christianson G, Manoguerra AS, Chyka PA, Caravati EM, Wax PM, Keyes DC, Woolf AD, Scharman EJ, Booze LL, Troutman WG; American Association of Poison Control Centers (2006). "Acetaminophen poisoning: an evidence-based consensus guideline for out-of- hospital management". Clin Toxicol (Phila). 44 (1): 1–18. PMID 16496488.
- ↑ Ferner, RE.; Dear, JW.; Bateman, DN. (2011). "Management of paracetamol poisoning". BMJ. 342: d2218. PMID 21508044.
- ↑ "http://www.acep.org/content.aspx?id=26830". Retrieved 10 January 2014. External link in
|title=
(help)